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ABSTRACT
Background Many studies have addressed chronic 
dysphagia resulting from chemoradiotherapy for head 
and neck cancer (HNC) because of its severity, but 
changes in the swallowing function during chemoradio-
therapy has been rarely reported. This study aimed to 
elucidate the changes in the swallowing function during 
chemoradiotherapy for HNC.
Methods From April 2018 to July 2020, 20 patients 
who underwent definitive or postoperative chemora-
diotherapy at our hospital for head and neck squamous 
cell carcinoma were evaluated by flexible endoscopy 
with the Hyodo scoring system for swallowing, the 
Penetration–Aspiration Scale (PAS), and the Functional 
Outcomes Swallowing Scale (FOSS).
Results Assessments at the start of treatment, at 40 
Gy, and at the end of treatment yielded these mean val-
ues: Hyodo score—0.39, 1.22, and 2.56; PAS—1.00, 1.05, 
and 1.5; FOSS—0.2, 0.55, and 1.1, respectively. The 
Dunn multiple comparison test was used for analysis 
to determine significance (P < 0.05). The Hyodo score 
and FOSS were significantly increased at the end of 
treatment versus initial evaluation; however, score was 
maintained at a tolerable level for oral intake. PAS did 
not show a significant increase.
Conclusion In conclusion, changes in the swallowing 
function during chemoradiotherapy for HNC were mild, 
and swallowing function was maintained at a tolerable 
level for oral intake.
Key words head and neck cancer; radiotherapy; swal-
lowing function
Chemoradiotherapy is a standard treatment for patients 
with locally advanced head and neck squamous cell car-
cinoma (HNSCC). Patients typically experience several 
acute adverse events during treatment, such as muco-
sitis, dermatitis, and dysphagia. Chemoradiotherapy 
also induces several chronic adverse events, such as dry 
mouth caused by salivary gland dysfunction, cardio-
vascular events, secondary cancers, and dysphagia, all 
of which negatively affect the patient’s quality of life.1, 2 
Several reports have addressed chronic dysphagia in 
this population because of its life-threatening sever-
ity1, 3–5; however, changes in the swallowing function 
during chemoradiotherapy has been rarely reported.6, 7
Lazarus et al. reported small number of cases eval-
uated by videofluorographic swallowing examination 
(VESE) before and after treatment to assess dysphagia 
during radiotherapy for HNSCC.6 The findings demon-
strated reduced posterior tongue base movement toward 
the posterior pharyngeal wall, and reduced laryngeal 
elevation during the swallowing. However, no infor-
mation was provided for objective scoring regarding 
swallowing and for actual oral intake. Few studies have 
addressed changes in the swallowing function during 
chemoradiotherapy for HNSCC; however, the effective-
ness of flexible endoscopic evaluation of swallowing 
(FEES) with the Hyodo scoring system was reported to 
predict aspiration.8, 9 This study performed FEES and 
VESE at the start of treatment, at 40 Gy, and the end 
of treatment to elucidate the changes in the swallowing 
function during chemoradiotherapy for HNSCC.
MATERIALS AND METHODS
Patients and Examinations
From April 2018 to July 2020, patients who underwent 
definitive or postoperative chemoradiotherapy at the 
authors’ hospital for HNSCC were evaluated with 
FEES with the Hyodo scoring system, VESE with the 
Penetration–Aspiration Scale (PAS), and the Functional 
Outcomes Swallowing Scale (FOSS) at the start of 
treatment, at 40 Gy, and at the end of treatment.
The Hyodo scoring method is the 4-point scale 
used to score the results of the f lexible endoscopic 
procedure to evaluate the feasibility of oral intake. This 
method comprises the following four evaluation points: 
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(1) salivary pooling at the vallecula and piriform sinus; 
(2) glottal closure ref lex induction by touching the 
epiglottis or arytenoid with the endoscope; (3) location 
of the bolus at a timing of swallowing reflex initiation; 
and (4) pharyngeal clearance after swallowing (Table 1). 
These four parameters are scored with a range of 0–3 on 
a 4-point scale, and the final score is calculated as the 
sum of each score in the four parameters. All patients 
underwent FEES examination with the Hyodo scoring 
method that was obtained by the transnasal flexible 
endoscopic view with the patient swallowing 3 mL 
colored water while in an upright seated position.
The Penetration–Aspiration Scale (PAS) is an 
8-point scale to evaluate the depth and response to 
airway invasion, which has been widely used as the 
method to score the results of VESE (Table 2). The PAS 
scale score is determined while a 5 mL barium swallow 
is administered to the patient in upright seated position. 
FOSS categorizes swallowing function into 6 stag-
es: stage 0, normal function and asymptomatic; stage 
Table 1. Flexible endoscopic evaluation of swallowing with the Hyodo scoring method
FEES with Hyodo scoring method
(1) The salivary pooling degree at the vallecula and piriform sinuses
0: No pooling
1: Pooling at the only vallecular
2: Pooling in vallecula and piriform sinuses and no penetration into larynx
3: Pooling in vallecula and piriform sinuses and penetration into larynx
(2) The glottal closure reflex induced by touching the epiglottis or arytenoid with the endoscope
0: Marked reflex by one touching
1: Slow and/or weak reflex by one touching
2: Reflex be two or three touching
3: No reflex despite three touching





(4) The extent of pharyngeal clearance after blue-dyed water is swallowed
0: No residue
1: Pharyngeal residues remain, but are absent after swallowing is attempted two or three times
2: Pharyngeal residues remain, but do not penetration into larynx
3: Pharyngeal residues remain and penetration into larynx
Table 2. Videofluorographic swallowing examination with the Penetration–Aspiration Scale
Penetration Aapiration Scale
1. Material does not enter the airway
2. Material enters the airway, remains above the vocal folds, and is ejected from the airway
3. Material enters the airway, remains above the vocal folds, and is not ejected from the airway
4. Material enters the airway, contacts the vocal folds, and is ejected from the airway
5. Material enters the airway, contacts the vocal folds, and is not ejected from the airway
6. Material enters the airway, passes below the vocal folds and is ejected into the larynx or out of the airway
7. Material enters the airway, passes below the vocal folds, and is not ejected from the trachea despite effort
8. Material enters the airway, passes below the vocal folds, and no effort is made to eject
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1, normal function with episodic or daily symptoms of 
dysphagia; stage 2, compensated abnormal function 
manifested by significant dietary modifications or pro-
longed mealtimes but without weight loss or aspiration; 
stage 3, decompensated abnormal function with weight 
loss of < 10% of body weight over 6 months caused by 
dysphagia or daily cough, gagging, or aspiration dur-
ing meals; stage 4, severely decompensated abnormal 
function with weight loss of > 10% of body weight over 
6 months caused by dysphagia or severe aspiration with 
bronchopulmonary complications; and stage 5, nonoral 
feeding for all nutrition.
In addition, patients were evaluated with the pa-
tient’s diet for each point using Complete International 
Dysphagia Diet Standardization Initiative (IDDSI) 
Framework Detailed Definition 2.0, 2019.10
Treatment
All patients underwent concurrent chemoradiotherapy 
for HNSCC. Cisplatin was administered every three 
weeks at a dose of 100 mg/m2 for three cycles concur-
rently with radiotherapy. Radiotherapy was performed 
5 days/week, and all patients received intensity-
modulated radiotherapy. The planned total dose to 
macroscopic disease (tumor/involved lymph nodes), and 
high-risk area because of positive margin for transoral 
surgery was set to 66 Gy (2 Gy/day, 33 fractions). All 
patients performed prophylactic swallowing exercise 
such as range of motion for lips, tongue, and larynx, 
Mendelsohn maneuver, and supraglottic swallowing 
during the treatment.
Analysis
Statistical analyses were conducted using GraphPad 
Prism 9 (GraphPad Software, San Diego, CA). The 
objective changes in the Hyodo score, PAS, and FOSS 
were compared by using the Dunn multiple comparison 
test. For all analyses, P < 0.05 was considered statisti-
cally significant.
Ethical declaration
The protocol of the investigation has been approved by 
the institutional review board of our university (No. 
19A101). This study was conducted in accordance with 
the Declaration of Helsinki (adopted by the World 
Medical Association General Assembly in Helsinki 
in 1964, including subsequent revisions) and “Ethical 
Guidelines for Medical and Health Research Involving 
Human Subjects” (December 2014, Ministry of 
Education, Culture, Sports, Science and Technology, 
Japan).11 In accordance with the “Ethical Guidelines 
for Medical and Health Research Involving Human 
Subjects,” informed consent for participation was 
obtained by providing study-related information on the 
home page and at our outpatient department.
RESULTS
This study evaluated 20 HNSCC cases for changes in 
the swallowing function during chemoradiotherapy 
(Table 3). Mean patient age was 64.5 years, and most 
patients (17 of 20) were male. All patients had good per-
formance status, and the Eastern Cooperative Oncology 
Group Performance Status (ECOG PS) score was 0 for 
all patients. Primary tumor sites were 1 in the nasophar-
ynx, 2 in oropharynx, 11 in hypopharynx, 3 in larynx, 
2 in maxillary sinus, 1 in the cervical lymph nodes 
as metastasis from an occult primary tumor. Clinical 
stages were 4 patients in stage II, 6 in stage III, and 10 
in stage IV. Median irradiation dose was 66 Gy with 33 
fractions, and all patients received intensity-modulated 
radiotherapy. Two patients received chemoradiotherapy 
in the postoperative setting because of positive margins 
with transoral surgery for oropharyngeal cancer. The 
other 18 patients received chemoradiotherapy in the 
definitive setting. All patients completed concurrent 
chemoradiotherapy without treatment interruption 
or delay. No patients had tracheostomy at the start 
of treatment; and three patients had unilateral vocal 
cord paralysis at the initial diagnosis. No patients had 
a history of aspiration pneumoniae. No patients had 
cognitive dysfunction or impaired consciousness during 
chemoradiotherapy.
Figure 1 shows the sequential changes of FEES 
assessed by the Hyodo score. The score was 0.39 at the 
initial evaluation, 1.22 at 40 Gy, and 2.56 at the end of 
treatment. The bar charts show means ± standard error 
of the mean (s.e.m.). The Hyodo score at the end of treat-
ment was significantly increased compared with the ini-
tial evaluation score on the Dunn multiple comparison 
test (P < 0.05). No significant difference was observed 
in the mean score between the initial evaluation and 40 
Gy and between 40 Gy and the end of treatment.
In sub-item, the mean of the salivary pooling 
degree at the vallecula and piriform sinuses was 0.22 at 
the initial evaluation, 0.5 at 40 Gy, and 1.0 at the end of 
treatment. Compared with the initial evaluation score 
on the Dunn multiple comparison test (P < 0.05), the 
salivary pooling degree was significantly higher at the 
end of the treatment.
The other mean values for each point are as fol-
lows: glottal closure reflex induction by touching the 
epiglottis or arytenoid with the endoscope—0, 0.06, and 
0.56; location of the bolus at a timing of swallowing re-
flex initiation—0.17, 0.39, and 0.5; pharyngeal clearance 
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after swallowing—0, 0.28, and 0.5, respectively. These 
scores did not significantly increase throughout the 
treatment.
Figure 2 shows the mean of PAS score for each 
point as follows: 1.00 at initial evaluation, 1.05 at 40 
Gy, and 1.5 at the end of treatment. The bar charts show 
means ± standard error of the mean (s.e.m.). No signifi-
cant difference in the mean score was observed between 
three data points on the Dunn multiple comparison 
test. Thus, the PAS score did not significantly increase 
throughout the treatment.
Figure 3 shows the sequential changes of FOSS. 
The score was 0.2 at the initial evaluation, 0.55 at 40 
Gy, and 1.1 at the end of treatment. The bar charts show 
means ± standard error of the mean (s.e.m.). The FOSS 
at the end of treatment was significantly increased 
compared with the initial evaluation score on the Dunn 
multiple comparison test (P < 0.05). No significant 
difference was observed in the mean score between the 
initial evaluation and 40 Gy and between 40 Gy and the 
end of treatment.
Table 4 shows the form of the patient’s diet at 
Table 3. Patient characteristics (n = 20)
Characteristics n %
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IMRT, intensity modulated radiation therapy; RT, radiation 
therapy.
Fig. 1. Sequential changes on flexible endoscopic evaluation of 
swallowing with the Hyodo scoring method. The bar charts show 
means ± standard error of the mean (s.e.m.). Statistical analysis 
was performed using the Dunn multiple comparison test. n.s., not 
significant.
Fig. 2. Sequential changes on the videofluorographic swallowing 
examination with the Penetration–Aspiration Scale (PAS). The 
bar charts show means ± standard error of the mean (s.e.m.). 
Statistical analysis was performed using the Dunn multiple com-
parison test. n.s., not significant.
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each point. At the start of treatment, all patients had a 
Level 7 regular oral diet. At 40 Gy, 3 patients required 
modification of the diet form. At the end of treatment, 
12 (60%) patients had maintained a Level 7 regular diet, 
1 (5%) patient was at Level 7 easy to chew, 2 (10%) pa-
tients were at Level 6, and 1 (5%) patient was receiving 
enteral nutrition transorally. In total, 16 (80%) patients 
continued oral diet intake and 4 (20%) patients required 
enteral nutrition using nasogastric tube at the end of 
treatment.
DISCUSSION
This study characterized to elucidate the changes in 
the swallowing function during chemoradiotherapy for 
HNSCC with objective scoring methods: FEES with 
the Hyodo scoring system, VESE with the PAS score, 
and FOSS. Chiba et al. reported that a Hyodo score > 6 
was the independent predictive factor for aspiration.8, 9 
In the present study, the Hyodo score at the end of 
treatment was 2.56, which was significantly increased 
compared with the score at initial evaluation. However, 
swallowing function was maintained at the tolerable 
level for oral intake at the end of treatment, with or 
without modification of the diet form. The mean value 
of FOSS at the end of treatment was 1.1, which was 
significantly increased. However, FOSS at the end of 
treatment was also maintained at tolerable level for oral 
intake without weight loss or aspiration. PAS was not 
significantly increased throughout the treatment, which 
supports the characterization of the dysphagia during 
chemoradiotherapy for HNSCC as not very severe, and 
the swallowing function was maintained at the tolerable 
level for oral intake. Swallowing function evaluated 
by FEES could become worse than that by VFSE as 
described previously, and VESE is thought to be a gold 
standard technique to evaluate swallowing function.12, 13 
The difference might have caused the dissociation of 
results between VESE and FEES.
Several studies reported that prophylactic swal-
lowing exercises before and during chemoradiotherapy 
were useful to prevent a swallowing dysfunction for 
patients with HNSCC after completing therapy.14–17 The 
range of motion exercise of the lips, jaw, tongue, and 
larynx is a frequent procedure in prophylactic swallow-
ing exercises and aims to improve the movement of the 
targeted structure and prevent the fibrosis induced by 
radiotherapy.12, 13 The Mendelsohn maneuver enhances 
the opening of the upper aerodigestive sphincter and 
improves pharyngeal clearance by prolongation laryn-
geal elevation during swallowing.12, 13 In our hospital, 
all patients who were treated with chemoradiotherapy 
for HNSCC received prophylactic swallowing exercise 
during the treatment, which may have been effective to 
maintain the swallowing function at the tolerable level 
for oral intake during chemoradiotherapy.
The results of this study showed that swallowing 
function was able to be maintained at the tolerable 
level for oral intake. In contrary the authors’ overall 
experience with patients with HNSCC who underwent 
chemoradiotherapy has been that these patients could 
not continue oral intake during chemoradiotherapy, 
especially at the end of treatment. This study also evalu-
ated actual oral intake and diet form using the Complete 
IDDSI Detailed Definitions 2.0, 2019 for each point 
(initial evaluation, at 40 Gy, and at end of treatment). 
Most patients (80%) could continue oral intake with or 
without diet form modification through the end of treat-
ment; however (20%) could not continue oral intake de-
spite maintaining their FEES, VESE, and FOSS scores. 
Oral intake is not affected only by swallowing function, 
but also by the pain, nausea, dysgeusia, and fatigue that 
result from chemotherapy and radiotherapy.18 Thus, it is 
critical to manage these symptoms to enable patients to 
continue the oral intake during chemoradiotherapy.
The radiation dose for cricopharyngeal muscle and 
Fig. 3. Sequential changes on the Functional Outcome 
Swallowing Scale (FOSS). The bar charts show means ± standard 
error of the mean (s.e.m.). Statistical analysis was performed using 
the Dunn multiple comparison test. n.s., not significant.
Table 4. Diet form during chemoradiotherapy
Diet form Start 40 Gy End
Level 7 Regular 20 17 12
Level 7 Easy to chew 0 2 1
Level 6 Soft & bite-sized 0 1 2
Level 3 Liquidised 0 0 1
Enteral nutrition (Nasogastric tube) 0 0 4
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cervical esophagus has been shown to be relevant for 
dysphagia during radiotherapy.7 In this study, ≥ Grade 3 
dysphagia according to Common Terminology Criteria 
for Adverse Events (CTCAE) version 4.0 was defined as 
dysphagia; however, dysphagia in CTCAE version 4.0 
is not only influenced by swallowing function but also 
by oral intake status. As discussed, oral intake is not 
affected only by swallowing function; therefore, dys-
phagia in CTCAE version 4.0 may not accurately reflect 
the pure swallowing function. In the present study, 11 
patients with hypopharyngeal cancer were included, and 
therefore the radiation dose for cricopharyngeal muscle 
and cervical esophagus may be relatively higher than 
that for patients with other types of HNSCC; however, 
results showed that deterioration of swallowing function 
were not severe. Despite the thought that pure swallow-
ing function may be maintained during chemoradio-
therapy, the pain, nausea, dysgeusia, and fatigue caused 
by chemotherapy and radiotherapy mainly results in a 
negative effect for maintaining the oral intake.
This study elucidated that deterioration of swal-
lowing function during chemoradiotherapy for HNC is 
not severe based on the objective scoring methods using 
the Hyodo score, PAS, and FOSS. Swallowing function 
was maintained at a tolerable level for oral intake at the 
end of treatment, although a minority of patients could 
not continue oral intake. Oral intake is affected not only 
by swallowing function but also by the pain, nausea, 
dysgeusia, and fatigue that result from chemotherapy 
and radiotherapy. Therefore, all of these symptoms 
should be managed to ensure that oral intake can be 
maintained.
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